Tolerance and Chimerism after Renal and Hematopoietic-Cell Transplantation

A patient received a kidney graft from his HLA-identical brother, followed by an infusion of CD34+ hematopoietic stem cells from the same donor. An apparent state of immunologic tolerance to the kidney allograft developed, allowing withdrawal of all immunosuppressive therapy within 6 months. A patie...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 358; no. 4; pp. 362 - 368
Main Authors Scandling, John D, Busque, Stephan, Dejbakhsh-Jones, Sussan, Benike, Claudia, Millan, Maria T, Shizuru, Judith A, Hoppe, Richard T, Lowsky, Robert, Engleman, Edgar G, Strober, Samuel
Format Journal Article
LanguageEnglish
Published Boston, MA Massachusetts Medical Society 24.01.2008
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A patient received a kidney graft from his HLA-identical brother, followed by an infusion of CD34+ hematopoietic stem cells from the same donor. An apparent state of immunologic tolerance to the kidney allograft developed, allowing withdrawal of all immunosuppressive therapy within 6 months. A patient received a kidney graft from his HLA-identical brother, followed by an infusion of CD34+ hematopoietic stem cells from the same donor. Immunologic tolerance to the kidney allograft developed, allowing withdrawal of all immunosuppressive therapy within 6 months. Immune tolerance of organ transplants has been induced in laboratory animals when persistent mixed blood and immune-cell chimerism has been achieved by infusing hematopoietic cells from the organ donor before or after transplantation of the organ. 1 – 3 The continued presence of the organ donor's immune cells in the recipient's thymus and peripheral lymphoid tissue promotes and maintains immune tolerance by eliminating T-cell clones that can react to alloantigens of the graft. 1 – 3 We have attempted to achieve persistent mixed chimerism and tolerance in humans after transplantation of combined HLA-matched kidney and hematopoietic cells, using a low-intensity conditioning regimen of total . . .
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa074191